MISCEND Trademark

Trademark Overview

On Friday, November 6, 2020, a trademark application was filed for MISCEND with the United States Patent and Trademark Office. The USPTO has given the MISCEND trademark a serial number of 90304082. The federal status of this trademark filing is SU - NON-FINAL ACTION - MAILED as of Thursday, November 21, 2024. This trademark is owned by Edwards Lifesciences Corporation. The MISCEND trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Providing medical and scientific research information in the field of heart disease and clinical trials
miscend

General Information

Serial Number90304082
Word MarkMISCEND
Filing DateFriday, November 6, 2020
Status807 - SU - NON-FINAL ACTION - MAILED
Status DateThursday, November 21, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 25, 2021

Trademark Statements

Goods and ServicesProviding medical and scientific research information in the field of heart disease and clinical trials

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, January 7, 2021
Primary Code042
First Use Anywhere DateTuesday, March 30, 2021
First Use In Commerce DateTuesday, March 30, 2021

Trademark Owner History

Party NameEdwards Lifesciences Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIrvine, CA 92614
Party NameEdwards Lifesciences Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92614

Trademark Events

Event DateEvent Description
Tuesday, November 10, 2020NEW APPLICATION ENTERED
Thursday, January 7, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, April 12, 2021ASSIGNED TO EXAMINER
Friday, April 16, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 5, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 25, 2021PUBLISHED FOR OPPOSITION
Tuesday, May 25, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 20, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 18, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, January 18, 2022SOU EXTENSION 1 FILED
Tuesday, January 18, 2022SOU EXTENSION 1 GRANTED
Thursday, January 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 20, 2022SOU EXTENSION 2 FILED
Wednesday, August 3, 2022PETITION TO REVIVE-GRANTED
Wednesday, August 3, 2022TEAS PETITION TO REVIVE RECEIVED
Wednesday, August 3, 2022SOU EXTENSION RECEIVED WITH TEAS PETITION
Wednesday, August 3, 2022NOTICE OF REVIVAL - E-MAILED
Monday, August 22, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 24, 2022SOU EXTENSION 2 GRANTED
Thursday, August 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 16, 2023SOU TEAS EXTENSION RECEIVED
Monday, January 16, 2023SOU EXTENSION 3 FILED
Monday, January 16, 2023SOU EXTENSION 3 GRANTED
Wednesday, January 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 19, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, July 19, 2023SOU EXTENSION 4 FILED
Wednesday, July 19, 2023SOU EXTENSION 4 GRANTED
Friday, July 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 17, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 17, 2024SOU EXTENSION 5 FILED
Monday, January 22, 2024SOU EXTENSION 5 GRANTED
Tuesday, January 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 22, 2024USE AMENDMENT FILED
Monday, July 22, 2024TEAS STATEMENT OF USE RECEIVED
Friday, July 26, 2024STATEMENT OF USE PROCESSING COMPLETE
Thursday, November 21, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, November 21, 2024NON-FINAL ACTION E-MAILED
Thursday, November 21, 2024SU - NON-FINAL ACTION - WRITTEN

Related Keywords

miscend heart disease clinical trials field information medical scientific research providing